AU2018266690A1 - Biodegradable microparticles for sustained delivery of anti-angiogenic peptide - Google Patents

Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Download PDF

Info

Publication number
AU2018266690A1
AU2018266690A1 AU2018266690A AU2018266690A AU2018266690A1 AU 2018266690 A1 AU2018266690 A1 AU 2018266690A1 AU 2018266690 A AU2018266690 A AU 2018266690A AU 2018266690 A AU2018266690 A AU 2018266690A AU 2018266690 A1 AU2018266690 A1 AU 2018266690A1
Authority
AU
Australia
Prior art keywords
present
microparticle
angiogenic peptide
sustained delivery
biodegradable microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018266690A
Other languages
English (en)
Inventor
Peter A. Campochiaro
Jordan J. Green
Jayoung Kim
Raquel LIMA E. SILVA
Adam MIRANDO
Niranjan Pandey
Aleksander S. Popel
Ron SHMUELI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Asclepix Therapeutics Inc
Original Assignee
Johns Hopkins University
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Asclepix Therapeutics Inc filed Critical Johns Hopkins University
Publication of AU2018266690A1 publication Critical patent/AU2018266690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018266690A 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide Abandoned AU2018266690A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (1)

Publication Number Publication Date
AU2018266690A1 true AU2018266690A1 (en) 2019-12-12

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018266690A Abandoned AU2018266690A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Country Status (8)

Country Link
US (1) US20200179285A1 (enExample)
EP (1) EP3621597A4 (enExample)
JP (1) JP2020518651A (enExample)
KR (1) KR20200003859A (enExample)
CN (1) CN111315364A (enExample)
AU (1) AU2018266690A1 (enExample)
CA (1) CA3063140A1 (enExample)
WO (1) WO2018208829A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018248297B2 (en) 2017-04-06 2020-09-17 Sustain Holdings, Llc Collagen peptide-based medicament compositions and devices and methods of production and use thereof
EP3661536A4 (en) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR
EA202192607A1 (ru) * 2019-03-26 2022-03-03 Асклепикс Терапьютикс, Инк. Композиции и способы для лечения глазного заболевания
US11389513B2 (en) 2019-04-22 2022-07-19 Sustain Holdings, Llc Collagen peptide-based medicament compositions and devices and methods of production and use thereof
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
WO2014145749A1 (en) * 2013-03-15 2014-09-18 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
EP3003343B1 (en) * 2013-06-07 2019-10-23 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
BR112019006735A2 (pt) * 2016-10-04 2019-06-25 Asclepix Therapeutics Llc compostos e métodos para ativação da sinalização de tie2

Also Published As

Publication number Publication date
WO2018208829A8 (en) 2019-07-04
CN111315364A (zh) 2020-06-19
EP3621597A4 (en) 2021-06-02
US20200179285A1 (en) 2020-06-11
CA3063140A1 (en) 2018-11-15
KR20200003859A (ko) 2020-01-10
EP3621597A1 (en) 2020-03-18
WO2018208829A1 (en) 2018-11-15
JP2020518651A (ja) 2020-06-25

Similar Documents

Publication Publication Date Title
AU2018266690A1 (en) Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
Motiei et al. Intrinsic parameters for the synthesis and tuned properties of amphiphilic chitosan drug delivery nanocarriers
MX346167B (es) Procedimientos para la preparacion de composiciones inyectables de liberacion controlada.
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
IL250652B2 (en) Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
WO2019075263A3 (en) Methods and compositions for topical delivery
EA201491185A1 (ru) Полимеры альфа-аминоамидинов и их применение
NZ629730A (en) Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
MX388028B (es) Suministro de antioxidantes bioactivos, nanoencapsulados.
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
WO2010125475A3 (en) Sustained release formulations comprising gnrh analogues
JP2018500394A5 (enExample)
WO2019238610A8 (en) Keratin nanofibers as delivery vehicles of active ingredients, methods for the production and uses thereof
PH12018500367A1 (en) Microparticle compositions comprising saflufenacil
RU2012145811A (ru) Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения
BR112016025016A2 (pt) composições de proteína de partículas pequenas e métodos de produção
SA520412229B1 (ar) تركيبات صيدلية لها فترة إطلاق مُختارة
EA201890698A1 (ru) Химически инертный термоплавкий клей с улучшителем времени схватывания
MX392770B (es) Composición farmacéutica de estabilidad mejorada.
EA201591111A1 (ru) Лекарственная дозированная форма, состоящая из полимерных частиц темозоломида
Tiash et al. Methotrexate-and cyclophosphamide-embedded pure and strontiumsubstituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells
ZA202403411B (en) Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof
WO2012172433A3 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
ZA202403104B (en) Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use
RU2014151603A (ru) Пептиды ledgf и их композиции для лечения дегенеративных заболеваний

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period